Nasdaq

Moleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E Warrants

The company is raising approximately $5.9 million through a public offering, which will provide necessary funding for advancing its drug candidates through clinical and preclinical development.
Seeking Alpha

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, ...

Vir Biotechnology stock hits 52-week high Tuesday - here's why

Vir Biotechnology Inc. VIR shares are up during Tuesday’s premarket session following a significant strategic collaboration with Astellas Pharma Inc. ALPMF ALPMY, better-than-expected fourth-quarter ...
Nasdaq

Moleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML Treatment

Moleculin Biotech, Inc. announced that the World Health Organization has approved “naxtarubicin” as the non-proprietary name for its next-generation anthracycline, Annamycin, which is being developed ...

Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary

Vir retains a 50-50 profit split and co-promotion option in the U.S., while receiving tiered double-digit royalties on ex-U.S ...
Business Insider

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 earnings call transcript

Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript February 17, 2026 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $1.72, expectations were $1.62. Operator: ...
Business Insider

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.
Seeking Alpha

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, ...
Insider Monkey

Is Moderna, Inc. (MRNA) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other ...

Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating

On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating.